Research

Life Sciences & Biotechnology

Title :

Synthesis and evaluation of novel dual GSK-3β/HDAC inhibitor as an anti-Alzheimer agent

Area of research :

Life Sciences & Biotechnology

Focus area :

Pharmaceuticals, Neurology

Principal Investigator :

Dr. Abha Sharma, Associate Professor, National Institute of Pharmaceutical Education and Research, Raebareli

Timeline Start Year :

2023

Timeline End Year :

2025

Contact info :

Details

Executive Summary :

A dual classical GSK-3β/epigenetic HDAC6 inhibitor is designed using a multi-target strategy for modulating Alzheimer's disease (AD) targets. The pyrimidone-based series of derivatives will be synthesized using four multistep schemes. The proposed molecules will undergo enzymatic assays, toxicity studies, acute toxicity, memory and cognitive improvement evaluation, and biochemical evaluation. Only one international research study is available.

Total Budget (INR):

37,31,040

Organizations involved